Cardinal opens new Nebraska facility to produce F-18
With the opening of a new facility in Omaha, Neb., that manufactures radiopharmaceuticals, Cardinal Health has created 30 jobs in the areas of nuclear pharmacy, health physics and radiopharmaceutical manufacturing.

The cyclotron will produce fluorine-18 (F-18), which is needed to create PET radiopharmaceuticals. In addition to F-18, the Dublin, Ohio-based company said the new cyclotron can produce other PET imaging agents to support oncology, neurology and cardiac imaging procedures, including radiopharmaceuticals for use in clinical trials.

The imaging agents produced at the facility will not only diagnose and treat disease at earlier stages, but also could help pharmaceutical companies evaluate efficacy of new therapeutic agents, Cardinal said.